Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 9,584 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: standard of care treatment Clear all
Recruiting Phase 2 Interventional

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

NCT07470606
View directory record Official record
Conditions
Brain Tumor
Interventions
Memantine, Raloxifene
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 2 Interventional Results available

Letermovir for CMV Prevention After Lung Transplantation

NCT05041426
View directory record Official record
Conditions
Lung Transplant, CMV
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Managing Medication-induced Constipation in Cancer: A Clinical Trial

NCT01416909
View directory record Official record
Conditions
Constipation
Interventions
Laxative Treatment, Standard of Care, Assessment Questionnaires
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 14, 2026, 9:56 AM EDT
Not yet recruiting Phase 2 Interventional

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

NCT07227909
View directory record Official record
Conditions
Psilocybin, Neuropathy
Interventions
Psilocybin (drug), Standard of Care (SOC)
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

NCT05482893
View directory record Official record
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers

NCT01693133
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care: Moist Wound Therapy and Offloading, EpiFix plus Standard of Care
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Bakersfield, California • Castro Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Phase 2 Interventional

NSAID Use After Robotic Partial Nephrectomy

NCT05842044
View directory record Official record
Conditions
Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions
Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth

NCT02712034
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MAT + A-CHESS, MAT
Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional Results available

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

NCT03365778
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 90 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 3 Interventional

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Interventions
Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
Drug · Other
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 14, 2026, 9:56 AM EDT
Active, not recruiting No phase listed Observational

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy

NCT03705416
View directory record Official record
Conditions
GERD, Obesity
Interventions
Endoscopy, Surgery
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Timeline
2019 – 2028
U.S. locations
6
States / cities
Baltimore, Maryland • New Hyde Park, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional Results available

Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer

NCT02823652
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm
Interventions
standard genetic education, Genetic Counseling, Genetic Testing, Internet-Based Intervention, Survey Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Not applicable Interventional

A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men

NCT07126548
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Best Practice, Discussion, Survey Administration, Virtual Reality
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional Results available

COPD Assessment and Management Bundle Versus Usual Care

NCT01833026
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Spirometry test, Levalbuterol
Device · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 14, 2026, 9:56 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

NCT07349693
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype
Interventions
Cerebraca wafer, Temozolomide (for relapsed malignant glioma)
Drug
Lead sponsor
Everfront Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease

NCT05534321
View directory record Official record
Conditions
Spine Metastases
Interventions
Prophylactic Radiotherapy, Standard of care systemic therapy
Radiation · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Active, not recruiting Phase 3 Interventional

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

NCT03769506
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Combination Product · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 14, 2026, 9:56 AM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 14, 2026, 9:56 AM EDT
Enrolling by invitation Phase 4 Interventional

Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries

NCT04933149
View directory record Official record
Conditions
Brachial Plexus Injury
Interventions
Ketamine Infustion
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Feasibility Study of Ultrasound Elastography Detecting Prostate Cancer

NCT03077126
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fleet Enema, Aixplorer® ShearWave Elastography (SWE™), Pre-surgery Ultrasound, Prostatectomy
Other · Device · Diagnostic Test + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT05131204
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Cemdisiran, Eculizumab, Pozelimab, Ravulizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Early Phase 1 Interventional

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

NCT06693284
View directory record Official record
Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
Interventions
mirdametinib and vorinostat
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intervening in Food Insecurity to Reduce and Mitigate (InFoRM) Childhood Obesity

NCT05586269
View directory record Official record
Conditions
Pediatric Obesity, Nutrition Disorders, Overnutrition, Child, Obesity
Interventions
Meal Kit Delivery, Newsletter + Food Pantry Referral
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 14, 2026, 9:56 AM EDT